Clinical Trials
2 trialsNCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT05170399 2026-02-05
Vaccine Responses in Patients With B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 4 Recruiting